Last Updated: 29 May 2025
Source: Statifacts
The global endoscopy and ambulatory surgical center market size accounted for USD 644.63 billion in 2024 and is predicted to touch around USD 893.7 billion by 2034, growing at a CAGR of 3.32% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 666.55 Billion |
| Market Size by 2034 | USD 893.7 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 3.32% |
The endoscopic and ambulatory surgical center market, being a part of healthcare services, offers minimally invasive diagnoses and surgeries, most of which are performed in patient-friendly environments. This market is on the rise, predominantly due to healthcare systems coming up with an immense emphasis on efficient, cost-effective, and patient-centered care. An ASC is an ambulatory center where medical procedures are carried out, including treatments required for day surgery, with minimally invasive procedures that pose high standards in care and low risk of infection, hence a fast recovery time, giving a whole new dimension to convenience. Unless in more complex settings, endoscopic procedures are slowly becoming an indispensable part of the ambulatory surgical procedures for diagnosis and intervention.
Therefore, the constant technological advancement in endoscopy from HD imaging to greater robotic assistance is positively correlated with higher accuracy and better outcomes of endoscopic procedures. The market, in turn, is fueled by the burgeoning incidence rates of chronic conditions, an aging population, and the burgeoning trend toward outpatient surgeries. All said, the number of ASCs is increasing rapidly, encouraged by changes in healthcare policies and reimbursement programs, along with the overall development of healthcare infrastructure in emerging nations.
“Outpatient surgery centers offer patients a convenient, community-based option to get quality surgical care from our trusted physicians, coupled with the ability to recover at home.”
“Our relationship with SurgNet has been unlike any other business relationship. Their commitment to excellence in healthcare and service to patients and providers is evident in every interaction.”
North America
North America dominated the market in 2024. North America enjoys dominance over the endoscopy and ambulatory surgical center market as a result of providing inpatient care and offering advanced healthcare infrastructures. The region offers a minimally invasive diagnostic endoscopy facility integrated with AI and robotic-assisted surgeries. An increasing prevalence of chronic diseases has provided instances for minimally invasive diagnostic and therapeutic procedures to act on. Reinforcing North American leadership are, among other things, supportive reimbursement frameworks and early lifting of medical innovations.
Asia-Pacific
Asia-Pacific is expected to witness the fastest growth during the forecast period. The Asia Pacific is projected to witness the fastest growth. Patient knowledge of the advantages of minimally invasive procedures and increased healthcare spending support market expansion in this region. The need for cheap and accessible outpatient services is triggered by the aging population. Government contributions for enhancing healthcare infrastructure are also supporting expansion in the market.
Europe
Europe is expected to witness significant growth in the market. EASC and endoscopy are booming in Europe, paralleling the cost benefits and patient preference for minimally invasive interventions. General awareness of early detection of diseases buoys the increasing use of endoscopic procedures in ambulatory settings.
The market is moderately fragmented, with local players like Olympus Corporation, Medtronic, Stryker, Ambu A/S, STERIS plc., PENTAX Medical (Hoya Corporation), Edward-Elmhurst Health, CHSPSC, LLC., Karl Storz GmbH & Co., KG, Nexus Day Surgery Centre, Pediatrix Medical Group, Prospect Medical Holdings, Inc., Boston Scientific Corporation, FUJIFILM Holdings Corporation, Eifelhöhen-Klinik AG, Envision Healthcare Corporation, Healthway Medical Group, SurgCenter, Surgery Partners, TH Medical, UNITEDHEALTH GROUP, etc. wishing to take the time to edge their presence through investments, partnerships, acquisitions, and mergers. They also invest in product development and competitive pricing. These strategies will promote market growth and lucrative opportunities for market players
Fujifilm Holdings' revenue for the twelve months ending December 31, 2024, was $20.659B, a 1.15% decline year-over-year. Fujifilm Holdings' annual revenue for 2024 was $20.43B, a 3.43% decline from 2023. Fujifilm Holdings' annual revenue for 2023 was $21.157B, a 5.88% decline from 2022.
According to Olympus's latest financial reports, the company's current revenue (TTM ) is £4.91 billion. In 2023, the company made a revenue of £5.06 billion, a decrease from the revenue in the year 2022, that were £5.48 billion.
Boston Scientific Corporation's full-year net sales were $16.7 billion. This represents growth of 17.6 percent on a reported basis, 18.5 percent on an operational basis, and 16.4 percent on an organic basis compared to 2023.
Published by Kesiya Chacko
